Behind the rosiglitazone controversy.

  title={Behind the rosiglitazone controversy.},
  author={Bernard Man Yung Cheung},
  journal={Expert review of clinical pharmacology},
  volume={3 6},
On 23 September 2010, the US FDA and the EMA issued statements announcing their response to data implicating the use of the antidiabetes drug rosiglitazone (Avandia(®), GlaxoSmithKline plc, London, UK) with an increased risk of cardiovascular events, including acute myocardial infarction and stroke. The EMA has implemented an immediate suspension of the drug, meaning that it will no longer be available in Europe. The FDA stopped short of a total suspension, but has stated that use of the drug… CONTINUE READING

Similar Papers

Loading similar papers…